• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞外对比剂增强 MRI:15 分钟延迟期可提高慢性肝病患者肝细胞癌的诊断性能。

Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.

机构信息

Department of Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University, College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.

出版信息

Eur Radiol. 2018 Apr;28(4):1551-1559. doi: 10.1007/s00330-017-5119-y. Epub 2017 Nov 13.

DOI:10.1007/s00330-017-5119-y
PMID:29134355
Abstract

OBJECTIVES

To determine the value of a 15-min delayed phase in extracellular contrast agent (ECA)-enhanced magnetic resonance imaging (MRI) for evaluation of hepatocellular carcinoma (HCC) in patients with chronic liver disease.

METHODS

Between 2014 and 2015, 103 patients with chronic liver disease underwent ECA-enhanced MRI; 133 lesions consisting of 107 HCCs, 23 benign lesions and three non-HCC malignancies were identified with pathological or clinical diagnosis. MRI images were reviewed by two abdominal radiologists independently using the European Association for the Study of the Liver (EASL) and Liver Imaging Reporting and Data System (LI-RADS) criteria. Imaging features observed in the 15-min delayed phase were recorded.

RESULTS

Of 107 HCCs, three or four additional HCCs were diagnosed according to the EASL criteria by adding the 15-min delayed phase, increasing sensitivity (Reviewer 1, from 69.2-72.0 % [P = 0.072]; Reviewer 2, from 75.7-79.4 % [P = 0.041]). Reviewers 1 and 2 upgraded one and four HCCs from LR-4 to LR-5 based on the LI-RADS, respectively. Among 23 benign lesions, no additional findings were observed in the 15-min delayed phase.

CONCLUSIONS

Including the 15-min delayed phase in ECA-enhanced MRI may improve the diagnostic performance for HCC in patients with chronic liver disease.

KEY POINTS

• Additional acquisition of 15-min delayed phase (FDP) requires approximately 20 s. • About 5 % of HCCs show washout or capsule appearance only in FDP. • Including FDP improves the sensitivity of extracellular contrast agent-enhanced MRI for HCC. • These results are applicable only to patients with chronic liver disease.

摘要

目的

探讨在慢性肝病患者中,使用细胞外对比剂(ECA)增强磁共振成像(MRI)行 15 分钟延迟扫描,对肝细胞癌(HCC)的诊断价值。

方法

回顾性分析 2014 年至 2015 年期间,103 例慢性肝病患者的 ECA 增强 MRI 资料。根据病理或临床诊断,共检出 133 个病灶,包括 107 个 HCC、23 个良性病变和 3 个非 HCC 恶性肿瘤。由 2 名腹部放射科医生独立使用欧洲肝脏研究协会(EASL)和肝脏影像报告和数据系统(LI-RADS)标准进行 MRI 图像评价。记录 15 分钟延迟期的影像学特征。

结果

根据 EASL 标准,在加入 15 分钟延迟期后,诊断出 3 个或 4 个 HCC,从而提高了诊断的敏感性(观察者 1:从 69.2%至 72.0%[P=0.072];观察者 2:从 75.7%至 79.4%[P=0.041])。观察者 1 和 2 根据 LI-RADS 将 1 个和 4 个 HCC 从 LR-4 升级为 LR-5。23 个良性病变中,在 15 分钟延迟期无新的发现。

结论

在 ECA 增强 MRI 中加入 15 分钟延迟期可能会提高慢性肝病患者 HCC 的诊断性能。

关键要点

  1. 额外采集 15 分钟延迟期(FDP)大约需要 20 秒。

  2. 大约 5%的 HCC 在 FDP 仅表现为洗脱或包膜样外观。

  3. 包括 FDP 可提高细胞外对比剂增强 MRI 对 HCC 的敏感性。

  4. 这些结果仅适用于慢性肝病患者。

相似文献

1
Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.细胞外对比剂增强 MRI:15 分钟延迟期可提高慢性肝病患者肝细胞癌的诊断性能。
Eur Radiol. 2018 Apr;28(4):1551-1559. doi: 10.1007/s00330-017-5119-y. Epub 2017 Nov 13.
2
Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.前瞻性应用肝脏成像报告和数据系统(LI-RADS)在钆塞酸增强 MRI 中的诊断准确性。
Eur Radiol. 2018 May;28(5):2038-2046. doi: 10.1007/s00330-017-5188-y. Epub 2017 Dec 11.
3
Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.钆塞酸二钠与细胞外对比剂磁共振成像用于肝脏影像报告与数据系统诊断肝细胞癌的前瞻性个体内比较。
Hepatology. 2018 Dec;68(6):2254-2266. doi: 10.1002/hep.30122. Epub 2018 Nov 12.
4
A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.一种改良的 LI-RADS:具有增强包膜的靶样肿瘤可被诊断为 HCC,而不是 LR-M 病变。
Eur Radiol. 2022 Feb;32(2):912-922. doi: 10.1007/s00330-021-08124-0. Epub 2021 Aug 4.
5
Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.肝脏影像报告和数据系统(LI-RADS)v2018:计算机断层扫描与钆塞酸增强磁共振成像的比较。
Jpn J Radiol. 2019 Sep;37(9):651-659. doi: 10.1007/s11604-019-00855-x. Epub 2019 Jul 18.
6
LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.LI-RADS 版本 2017 与版本 2018:钆塞酸二钠增强 MRI 诊断肝细胞癌。
Radiology. 2019 Sep;292(3):655-663. doi: 10.1148/radiol.2019182867. Epub 2019 Jul 16.
7
Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA.肝细胞癌的影像学特征:钆塞酸二钠(Gd-EOB-DTPA)增强 MRI 与 Gd-DTPA 的定量和定性比较
Invest Radiol. 2019 Aug;54(8):494-499. doi: 10.1097/RLI.0000000000000562.
8
Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.超顺磁性氧化铁增强 MRI 成像在肝硬化肝脏肝细胞癌无创成像诊断中的附加价值。
Invest Radiol. 2009 Dec;44(12):800-7. doi: 10.1097/RLI.0b013e3181bc271d.
9
Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI.钆塞酸二钠增强肝脏磁共振成像中双门静脉期的个体内比较用于肝细胞癌的无创诊断
Eur Radiol. 2021 Feb;31(2):824-833. doi: 10.1007/s00330-020-07162-4. Epub 2020 Aug 26.
10
Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation.LI-RADS 与其他非侵入性肝脏 MRI 标准以及影像学意见在使用钆塞酸增强 MRI 与组织病理标本相关性诊断肝硬化肝脏肝细胞癌中的比较。
Clin Radiol. 2021 May;76(5):333-341. doi: 10.1016/j.crad.2020.12.007. Epub 2021 Jan 16.

引用本文的文献

1
Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis.LI-RADS 类别 5 与类别 4 和 5 联合的表现:系统评价和荟萃分析。
Eur Radiol. 2024 Nov;34(11):7025-7040. doi: 10.1007/s00330-024-10813-5. Epub 2024 May 29.
2
The timing phase affected the inconsistency of APHE subtypes of liver observations in patients at risk for HCC on the multi-hepatic arterial phase imaging.时间分期影响了多肝动脉期成像中 HCC 高危患者的 APHE 亚型肝观察的不一致性。
Abdom Radiol (NY). 2024 Apr;49(4):1092-1102. doi: 10.1007/s00261-023-04096-5. Epub 2024 Jan 10.
3
HCC or Something Else? Frequency of Various Benign and Malignant Etiologies in Cirrhotic Patients with Newly Detected Focal Liver Lesions in Relation to Different Clinical and Sonographic Parameters.

本文引用的文献

1
Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging.肝脏影像报告和数据系统 CT 和钆塞酸增强 MRI 与弥散加权成像。
Eur Radiol. 2017 Oct;27(10):4394-4405. doi: 10.1007/s00330-017-4804-1. Epub 2017 Apr 3.
2
Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm.肝脏影像报告和数据系统(LI-RADS)2014版:诊断算法的理解与应用
Clin Mol Hepatol. 2016 Jun;22(2):296-307. doi: 10.3350/cmh.2016.0028.
3
Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial.
肝细胞癌还是其他病症?肝硬化患者新发现局灶性肝病变的各种良性和恶性病因的发生率与不同临床及超声参数的关系
Diagnostics (Basel). 2022 Aug 28;12(9):2079. doi: 10.3390/diagnostics12092079.
4
Evaluation of liver tumor identification rate of volumetric-interpolated breath-hold images using the compressed sensing method and qualitative evaluation of tumor contrast effect via visual evaluation.使用压缩感知方法评估容积内插屏气图像的肝脏肿瘤识别率,并通过视觉评估对肿瘤对比效果进行定性评估。
Quant Imaging Med Surg. 2022 May;12(5):2649-2657. doi: 10.21037/qims-21-850.
5
Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis.肝脏影像报告和数据系统在肝脏肿瘤特征描述中的临床应用:一项荟萃分析。
Diagnostics (Basel). 2021 Feb 17;11(2):323. doi: 10.3390/diagnostics11020323.
6
Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?钆塞酸增强 MRI 用于诊断慢性肝病患者肝细胞癌:门静脉晚期低信号可以替代廓清吗?
Abdom Radiol (NY). 2020 Sep;45(9):2705-2716. doi: 10.1007/s00261-020-02553-z.
7
Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?肝细胞癌:钆塞酸增强磁共振和弥散加权成像的 LI-RADS v2017 能否提高诊断准确性?
World J Gastroenterol. 2019 Feb 7;25(5):622-631. doi: 10.3748/wjg.v25.i5.622.
8
Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.肝脏影像报告和数据系统(LI-RADS)2018 版:高危患者肝细胞癌的影像学表现。
Radiology. 2018 Dec;289(3):816-830. doi: 10.1148/radiol.2018181494. Epub 2018 Sep 25.
钆塞酸二钠增强磁共振成像在诊断结直肠癌肝转移中的成本评估:VALUE试验结果
Eur Radiol. 2016 Nov;26(11):4121-4130. doi: 10.1007/s00330-016-4271-0. Epub 2016 Feb 24.
4
A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases.扩散加权和钆塞酸增强磁共振成像在肝转移瘤检测中的荟萃分析。
Eur Radiol. 2016 Dec;26(12):4595-4615. doi: 10.1007/s00330-016-4250-5. Epub 2016 Feb 16.
5
Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.肝细胞癌 ⩽3 cm 的肝细胞特异性对比增强磁共振成像的诊断标准。
J Hepatol. 2016 May;64(5):1099-1107. doi: 10.1016/j.jhep.2016.01.018. Epub 2016 Jan 25.
6
Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.钆塞酸二钠增强MRI鉴别慢性肝病患者不同原发性肝肿瘤的影像预测指标:分类树分析
Eur Radiol. 2016 Sep;26(9):3102-11. doi: 10.1007/s00330-015-4136-y. Epub 2015 Dec 3.
7
Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease.慢性肝病患者早期肝细胞癌的生长速率
Clin Mol Hepatol. 2015 Sep;21(3):279-86. doi: 10.3350/cmh.2015.21.3.279. Epub 2015 Sep 30.
8
Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.钆塞酸二钠增强肝脏磁共振成像上肝内肿块型胆管癌与肝细胞癌的鉴别诊断
Eur Radiol. 2016 Jun;26(6):1808-17. doi: 10.1007/s00330-015-4005-8. Epub 2015 Sep 15.
9
ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.欧洲胃肠道和腹部放射学会关于肝脏磁共振成像及肝脏特异性对比剂临床应用的共识声明。
Eur Radiol. 2016 Apr;26(4):921-31. doi: 10.1007/s00330-015-3900-3. Epub 2015 Jul 21.
10
Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.肝细胞癌:多排 CT 和 MR 成像的诊断性能——系统评价和荟萃分析。
Radiology. 2015 Apr;275(1):97-109. doi: 10.1148/radiol.14140690. Epub 2015 Jan 5.